Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.

[1]  C. Roehrborn,et al.  Natural history of ‘second’ biochemical failure after salvage radiation therapy for prostate cancer: a multi‐institution study , 2018, BJU international.

[2]  L. Egevad,et al.  Effect of Comorbidity on Prostate Cancer–Specific Mortality: A Prospective Observational Study , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Kantoff,et al.  Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Renshaw,et al.  Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial , 2017, JAMA oncology.

[5]  R. Mehra,et al.  Very Early Salvage Radiotherapy Improves Distant Metastasis‐Free Survival , 2017, The Journal of urology.

[6]  D. Grignon,et al.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.

[7]  B. Dubray,et al.  Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. , 2016, The Lancet. Oncology.

[8]  U. Capitanio,et al.  Predicting survival of men with recurrent prostate cancer after radical prostatectomy. , 2016, European journal of cancer.

[9]  Christopher J Kane,et al.  Prostate Cancer, Version 1.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  P. Kantoff,et al.  The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). , 2015, Journal of the National Cancer Institute.

[11]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[12]  J. Bahary,et al.  Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer , 2014 .

[13]  N. Willich,et al.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. , 2014, European urology.

[14]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.

[15]  A. D'Amico,et al.  Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. , 2012, The Lancet. Oncology.

[16]  J. Chin,et al.  UPDATE OF SWOG 8794: ADJUVANT RADIOTHERAPY FOR PT3 PROSTATE CANCER IMPROVES METASTASIS FREE SURVIVAL , 2008 .

[17]  Richard K Valicenti,et al.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Sandler,et al.  Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. , 2006, International journal of radiation oncology, biology, physics.

[19]  A. D'Amico,et al.  Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. , 2005, The Journal of urology.

[20]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.

[21]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[22]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[23]  A. Zietman,et al.  Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. , 1996, Urology.

[24]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.